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The Effect of Moderate Dietary Protein and Phosphate Restriction
on Calcium-Phosphate Homeostasis in Healthy Older Cats
R.F. Geddes, V. Biourge, Y. Chang, H.M. Syme, and J. Elliott
Background: Dietary phosphate and protein restriction decreases plasma PTH and FGF-23 concentrations and improves
survival time in azotemic cats, but has not been examined in cats that are not azotemic.
Hypothesis: Feeding a moderately protein- and phosphate-restricted diet decreases PTH and FGF-23 in healthy older cats
and thereby slows progression to azotemic CKD.
Animals: A total of 54 healthy, client-owned cats (≥ 9 years).
Methods: Prospective double-blinded randomized placebo-controlled trial. Cats were assigned to test diet (protein
76 g/Mcal and phosphate 1.6 g/Mcal) or control diet (protein 86 g/Mcal and phosphate 2.6 g/Mcal) and monitored for
18 months. Changes in variables over time and effect of diet were assessed by linear mixed models.
Results: A total of 26 cats ate test diet and 28 cats ate control diet. There was a significant effect of diet on urinary frac-
tional excretion of phosphate (P = 0.045), plasma PTH (P = 0.005), and ionized calcium concentrations (P = 0.018), but not
plasma phosphate, FGF-23, or creatinine concentrations. Plasma PTH concentrations did not significantly change in cats fed
the test diet (P = 0.62) but increased over time in cats fed the control diet (P = 0.001). There was no significant treatment
effect of the test diet on development of azotemic CKD (3 of 26 (12%) test versus 3 of 28 (11%) control, odds ratio 1.09
(95% CI 0.13–8.94), P = 0.92).
Conclusions and Clinical Importance: Feeding a moderately protein- and phosphate-restricted diet has effects on calcium-
phosphate homeostasis in healthy older cats and is well tolerated. This might have an impact on renal function and could be
useful in early chronic kidney disease.
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The prevalence of chronic kidney disease (CKD) incats is high1 and increases with age,2 making it
likely that a large number of older cats could have non-
azotemic CKD. Thirty-one percent of nonazotemic cats
≥9 years of age develop azotemic CKD by 12 months.3
Previous studies have looked at biomarkers for early
CKD,4–8 risk factors for CKD9,10, and predictors of
azotemia development,3,10 but at present, identification
of cats with nonazotemic CKD remains difficult.
In humans, the collection of clinical, biochemical, and
imaging abnormalities ultimately leading to renal osteodys-
trophy is now termed “chronic kidney disease-mineral and
bone disorder” (CKD-MBD).11 Cats have disruption of
calcium-phosphate homeostasis in CKD, with hyperphos-
phatemia, hyperparathyroidism, decreased calcitriol and
ionized calcium,12 and increased FGF-23 concentrations.13
Additionally, cats with late-stage CKD have decreased
bone quality, with an increased number of bone resorption
cavities in their femurs and decreased bone mineral density
compared to healthy cats.14 Taken together, these data
support the use of the term CKD-MBD in cats with CKD.
In humans, CKD-MBD biochemical changes occur early
in CKD to maintain a normal serum phosphate concentra-
tion in the face of declining glomerular filtration rate
(GFR). Similarly, both parathyroid hormone (PTH) and
fibroblast growth factor 23 (FGF-23) are increased in
healthy older cats that develop CKD within 12 months
compared to cats remaining nonazotemic,15,16 suggesting
that stimulation of phosphaturic hormones occurs to help
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FGF-23 fibroblast growth factor 23
FOS fructo-oligo-saccharides
GFR glomerular filtration Rate
GLM New Zealand green-lipped mussel extract
iCa ionized calcium
LoD limit of detection
MCS muscle condition score
NFE nitrogen-free extract
PTH parathyroid hormone
SBP systolic blood pressure
SRHP secondary renal hyperparathyroidism
TT4 total thyroxine
UPC urine protein-to-creatinine ratio
USG urine specific gravity
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maintain phosphate balance in the preazotemic stages of
CKD.
Dietary phosphate restriction is considered the main-
stay of treatment for naturally occurring azotemic CKD
in cats. Commercially available diets containing low
protein (≤60.2 g/MCal) and phosphate (≤1.0 g/MCal)
reduce plasma PTH concentration and improve survival
time in azotemic cats compared to cats eating mainte-
nance adult diets with approximately 120 g/MCal pro-
tein and 4.8 g/MCal phosphate.17 Additionally, a diet
marketed for cats with CKD containing restricted pro-
tein (≤67.4 g/MCal) and phosphate (≤1.2 g/MCal)
reduces the incidence of uremic crises and renal-related
deaths when compared to a maintenance diet containing
protein >92.0 g/MCal and phosphate ≥1.8 g/MCal.18
Plasma FGF-23 concentrations significantly decrease
after 28–56 days of feeding a diet containing low pro-
tein ≤66.5 g/MCal and phosphate ≤1.1 g/MCal in cats
with stable azotemia.19 However, feeding a protein
(69.7 g/MCal)- and phosphate (1.0 g/MCal)-restricted
diet instead of a high-protein (129.4 g/MCal) and high-
phosphate (3.4 g/MCal) diet to young adult cats (2–
3 years of age) over a short time period (4 weeks)
resulted in higher plasma creatinine and phosphate con-
centrations, which was postulated to be because of a
decrease in glomerular filtration rate (GFR).20
The benefit of phosphate and protein restriction in
healthy older cats is unknown. The overall aim (pri-
mary outcome) of this study was to examine whether
feeding a moderately protein (76 g/MCal)- and phos-
phate (1.6 g/MCal)-restricted diet to cats ≥9 years of
age could prevent progression to azotemic CKD, com-
pared to feeding a maintenance diet with protein 86
g/MCal and phosphate 2.6 g/MCal. More specifically,
to examine whether moderate phosphate restriction
would result in decreased fractional excretion of phos-
phate and reduced plasma PTH and FGF-23 concentra-
tions in healthy cats.
Materials and Methods
Animal Selection
Cats were recruited prospectively into this randomized double-
blinded controlled trial. The study protocol was approved by the
Ethics and Welfare Committees of the Royal Veterinary College
(URN 2011 1113) and Royal Canin. Clients of the Beaumont
Sainsbury Animal Hospital were invited to bring apparently
healthy cats ≥9 years of age to the clinic for free screening, with
the incentive of receiving free food for 18 months for eligible cats.
All cats seen between October 2011 and January 2013 were
screened. Owners were requested to withhold food from their cat
for at least 8 hours before appointments. The protocol followed at
each visit is outlined in Figure 1.
Cats were considered eligible for the trial if they were healthy
on physical examination and had no outward signs of illness
reported by their owners, with the exception of signs of
osteoarthritis. Auscultation of a heart murmur, documentation of
dental calculus  gingivitis, and palpation of small kidneys were
not exclusion criteria. Cats with plasma creatinine concentration
>2 mg/dL were excluded unless they had a concurrent USG of
≥1.035. If no cystocentesis sample could be collected, the cat was
reevaluated 1–2 weeks later and cats with persistent azotemia were
excluded, unless a USG ≥1.035 was documented. Cats were
excluded if they had long-term medical problems within the last 6
months; a plasma total thyroxine (TT4) >40 nmol/L; recent recur-
rent lower urinary tract problems; or were currently being fed on
a diet formulated for urinary tract conditions. Cats diagnosed with
systemic hypertension, defined as systolic blood pressure (SBP)
>160 mmHg with concurrent evidence of hypertensive retinopathy
or mean SBP >170 mmHg on two occasions without evidence of
hypertensive retinopathy, were treated with amlodipine besylatea
and reevaluated before enrollment.
Randomization and Blinding
Owners of cats that met the inclusion criteria were invited to
take part in the 18-month clinical trial. Consent was obtained
from all owners. Cats were entered onto a randomization list by
the same veterinary nurse for all cases, in strict chronologic order.
The only exception was that eligible cats from the same household
were assigned to the same diet (in total 4 households, each with 2
cats).
The food manufacturer assigned code names to the diets and
labeled plain white bags with the code, a feeding guide, and an
expiry date. The code was unblinded only after all analyses had
been completed.
Test and Control Diets Used
The test diet used was a commercially available dry diet formu-
lated for cats, marketed as a “senior” diet.b To manufacture the
control diet, any ingredients not normally present in an adult
maintenance diet for cats were removed from the test diet, and
protein and phosphate concentrations were adjusted to be similar
Fig 1. A timeline detailing when owners were requested to bring their cats into the clinic during the trial. All visits included history taking
(including the completion of questionnaires detailing dietary history), measurement of systolic blood pressure, physical examination includ-
ing assessment of bodyweight and body condition score, and dispensing of more diet as required. Sampling visits additionally included
jugular venepuncture and cystocentesis for acquisition of blood and urine samples, respectively.
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to commercial adult maintenance diets. Both diets were formulated
with the same ingredients with the exception of a few additional
ingredients in the test diet; the nutritional composition and ingre-
dients for each diet are shown in Table 1. The cholecalciferol
(1000 IU/kg) and iodine (5 ppm) contents of both diets were the
same, and both were formulated to induce a urine pH of 6–6.5 to
reduce the incidence of struvite urolithiasis. Both diets provided all
nutrients in excess of the National Research Council-recommended
nutrient requirements for cats.21 The test diet was lower in protein,
higher in omega (x)-3 polyunsaturated fatty acids (PUFA), and
lower in calcium and phosphate when compared to the control
diet. Owners were given guidance on weight of the dry trial diet to
feed per day based on bodyweight. The amount was tailored to
help achieve weight loss in cats with a body condition score >6 of
9. Owners were encouraged not to feed any other food. Owners
insistent on feeding a wet food were requested to feed a maximum
of 50 g per day, to avoid all fish-flavored foods and to avoid other
“senior” diets. To maximize compliance, owners were asked to
only rarely provide other foods (e.g., chicken, dairy) and treats.
Owners were requested to keep a daily diary of all foods given to
their cat during the trial period. Owners were encouraged to
ensure that at least 66% of their cat’s daily food intake (by vol-
ume) was the assigned diet. Because dry food has approximately 4
times more calories per gram than wet food, this was to ensure
that the majority of the calorific intake of the cat (≥approximately
80%) would come from the study diets. In a previous study, feed-
ing a protein (60.3 g/Mcal)- and phosphate (1.0 g/Mcal)-restricted
diet as at least two-third of the daily energy requirements was suf-
ficient to see a significant effect on plasma phosphate concentra-
tion in cats with azotemic CKD.17,22
Study Follow-Up
The schedule of clinic visits for this 18-month trial is shown in
Figure 1. At each visit, owners were questioned about dietary
compliance and perceived palatability. The cats had their systolic
blood pressure measured by Doppler, as previously described, and
had a physical examination including measurement of bodyweight.
Body condition score (BCS) was determined from 1 to 9 and mus-
cle condition score (MCS) scored as normal (4), mild (3), moder-
ate (2), or severe (1) muscle loss by the MCS system proposed by
WSAVA.c
The following data were obtained at visits 1, 2, 4, 6, and 8.
Blood samples were obtained by jugular venepuncture and urine
samples collected by cystocentesis. Ionized calcium (iCa) was mea-
sured on whole blood immediately after sampling with a portable
analyzer.d Heparinized plasma was submitted to an external labo-
ratory for biochemical analysis (and TT4 analysis on visits 1 and
6).e Urinalysis and sediment examination were performed in house.
Residual heparinized plasma, EDTA plasma, and urine were
stored at 80°C. Batch analysis was performed at the external lab-
oratory for urine protein-to-creatinine ratio (UPC) and urine
phosphate. Batch analysis was performed in house to measure
plasma FGF-23f and PTHg concentrations, as previously
described.13 These data were also obtained at other time points if
a cat became unwell during the study.
Development of azotemic CKD, death/euthanasia, and reach-
ing visit 8 on the allocated intervention were considered trial
end points. Renal azotemia was defined as a plasma creatinine
concentration >2 mg/dL with concurrent urine specific gravity
(USG) <1.035, or persistent azotemia on two consecutive occa-
sions at least 2 weeks apart without evidence of a prerenal
cause. Owners were instructed to follow the trial protocol until
confirmation of azotemia in cases where no urine sample was
obtained. If USG was documented to be >1.035, the study pro-
tocol was continued regardless of the plasma creatinine concen-
tration. The trial was terminated if a cat refused to eat the trial
diet; an owner repeatedly failed to attend appointments; a cat
developed a significant medical condition requiring additional
treatment; or adverse effects were observed that required cessa-
tion of the diet. All reasons for trial termination were recorded.
Cases where no data were obtained while on the assigned inter-
vention were excluded from analyses. Data for all other cases
Table 1. Ingredients for the test and control diets and
mean dietary composition from three batches of each
diet, as provided by the manufacturer. Nutrients
expressed per Mcal of metabolizable energy with energy
calculated by the National Research Council 2006 equa-
tion. Underlined ingredients were only present in the
test diet and not in the control diet. Nutrients high-







Energy (Kcal/Kg) 3822  29 3736  15
Water (g/Mcal) 13.9  1.59 15.3  2.34
Protein (g/Mcal) 76.0  1.13 85.5  2.16
Fat (g/Mcal) 37.2  1.13 36.7  1.25
Fatty Acids x3 (g/Mcal) 2.34  0.61 0.95  0.15
Fatty Acids x6 (g/Mcal) 9.49  0.85 10.1  1.29
Fatty Acids x6/x3 4.18  0.74 10.7  1.18
C18:2 Linoleic Acid x6
(g/Mcal)
9.09  0.81 9.84  1.24
C18:3 Gamma-linoleic
Acid x6 (g/Mcal)
0.09  0.02 0.04  0.00
C20:4 Arachidonic
Acid x6 (g/Mcal)
0.14  0.02 0.15  0.04
C20:5 EPA (g/Mcal) 0.88  0.33 0.03  0.01
C22:6 DHA (g/Mcal) 0.46  0.07 0.03  0.01
NFE (g/Mcal) 106  2.44 97.9  2.70
Starch (g/Mcal) 90.5  2.59 80.7  1.03
Cellulose (g/Mcal) 13.2  1.32 14.4  0.69
Total dietary fibre (g/Mcal) 28.9  1.22 31.6  1.74
Minerals (g/Mcal) 15.3  0.87 17.9  0.37
Calcium (g/Mcal) 1.93  0.18 2.87  0.19
Phosphate (g/Mcal) 1.59  0.05 2.61  0.15
Sodium (g/Mcal) 1.27  0.08 1.20  0.09
Potassium (g/Mcal) 2.09  0.13 2.10  0.12
Chloride (g/Mcal) 2.31  0.08 1.73  0.18
Ingredients Maize, wheat gluten, maize
flour, dehydrated poultry
protein, wheat, maize gluten,
animal fats, rice, vegetable
fibres, hydrolyzed animal
proteins, chicory pulp, fish
oil, soya oil, minerals, tomato
(source of lycopene), psyllium






marigold extract (source of
lutein), hydrolyzed cartilage
(source of chondroitin)
NFE, nitrogen-free extract; FOS, fructo-oligo-saccharides;
GLM, New Zealand green-lipped mussel extract; EPA, eicosapen-
taenoic acid; DHA, docosahexaenoic acid.
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were included until the study end point or termination of the
trial.
Statistical Analysis
Assuming 33% of cats on the control diet would develop azote-
mic CKD during the study period, and that <5% cats would
develop azotemia on the test diet, with a 5% type I error rate and
power of 80%, a sample size calculation suggested 30 cats would
be required in each group. Statistical analyses were performed by
SPSS.h Statistical significance was determined as P < .05. Normal-
ity of variables was assessed by visual inspection of histograms.
Results are reported as mean  SD for normally distributed vari-
ables or as median [25th, 75th percentiles] for data not normally
distributed. Variables at baseline were compared between groups
by independent t-tests or Mann-Whitney U-tests, as appropriate.
Proportions were compared between groups by a Fisher’s exact
test. Treatment effect reported as an odds ratio with 95% confi-
dence intervals (CI).
Fractional excretion of phosphate was calculated by the follow-
ing formula:
Linear mixed-effects models were constructed to compare the
change in continuous variables across all visits and study the effect
of diet on the changes identified. Variables with highly skewed dis-
tributions were logarithmically transformed. Data from all visits,
including additional recheck visits, if performed, were included.
Case number was treated as a random factor; all other variables
were fixed factors. Time was treated as a continuous covariate
with the unit expressed as month (28 days). Quadratic terms for
time (time2) were included in initial models to account for poten-
tial nonlinear changes of variables over time and subsequently
removed if not significant. Contrast analysis was performed post-
hoc to examine differences between the two diet groups at specific
time intervals in variables with a significant diet*time interaction.
Generalized estimating equations by ordinal logistic link func-
tion were constructed to compare the change in categorical vari-
ables across all visits and the effect of diet. An exchangeable
correlation structure was used to account for correlation among
repeated measures from the same cat. Fixed factors and covariates
were included as described above.
Results
One hundred and forty-five cats were assessed for eligi-
bility for the trial with a median age of 12.8 [11.2, 13.8]
(range 9.0–21.0) years. Case enrollment, diet allocation,
and follow-up are summarized in a flow diagram as per
the CONSORT 2010 statement23 (Fig 2). Additional
information not included in Figure 2 is outlined below.
Reasons for not meeting the inclusion criteria
included a diagnosis of azotemic CKD (n = 21), border-
line CKD diagnosis with conflicting results on follow-
up (n = 6), TT4 > 40 nmol/L (n = 16), recurrent lower
urinary tract problems/eating a urinary diet (n = 4), eat-
ing a prescription dieti (n = 1), taking long-term medi-
cation for suspected cardiovascular disease (n = 2), a
diagnosis of diabetes mellitus (n = 2), and chronic eye
problems (n = 1).
Medical problems diagnosed during the trial, which
necessitated trial termination, were congestive heart fail-
ure (n = 1) for a cat on the test diet and severe weight
loss (n = 1), hepatitis (n = 1), and diabetes mellitus
(n = 1) for cats on the control diet.
Medications administered during the trial to cats
assigned to the test diet included short-term antibiotics
for a cat bite abscess (n = 1), amlodipine besylate
(n = 1), long-term NSAIDs for osteoarthritis (n = 5),
and short-term NSAIDs (n = 3). Additionally, one cat
received medications for pancarpal arthrodesis surgery
for a short period of time, which occurred between vis-
its 4 and 6. Medications administered during the trial to
cats assigned to the control diet included amlodipine
besylate (n = 1), clomipramine hydrochloride to manage
urine spraying (n = 1), antibiotics for a urinary tract
infection (n = 1), and long-term NSAIDs for
osteoarthritis (n = 1). Additionally, methimazolej was
administered to one cat that was diagnosed with hyper-
thyroidism (TT4 64.1 nmol/L) at visit 6 and was
promptly and successfully treated medically, becoming
euthyroid (TT4 30.1 nmol/L) within 2 months and
remaining euthyroid at visits 7 and 8. There was no sig-
nificant difference between the proportion of cats
requiring long-term NSAIDs between groups (test
group 19% and control group 4%; P = 0.067).
Twenty-six cats that received test diet and 28 cats
that received control diet were included in analyses
(Fig 2). Baseline variables were similar between groups,
although UPC measurements were significantly higher
in cats assigned to receive control diet (see Table 2).
Effect of Diet Over Time
The median [range] timings for visits 2–8 were visit 2:
35 days [28–56], visit 3: 105 days [70–140], visit 4:
189 days [140–233], visit 5: 287 days [245–322], visit 6:
368 days [315–413], visit 7: 462 days [420–497], and visit
8: 553 days [474–595]. On six occasions, additional vis-
its occurred during the study period for the following
reasons: to confirm the presence of azotemic CKD (4
visits) or to assess control of hyperthyroidism (2 visits).
On 24 occasions, cats were not presented to the clinic,
of which 23 of 24 were nonsample visits; whenever pos-
sible, compliance with the assigned diet was checked by
telephone in this circumstance.
The proportion of cats lost from the trial because of
poor compliance was not significantly different between
groups (9 of 37 test vs. 3 of 32 control, P = 0.10). For
the 54 cats included in the analyses, the amount of diet
eaten was recorded as <66% on 11 of 284 occasions,
but was always ≥50%. There was no difference in per-
centage of diet eaten between the groups (P = 0.74) or
change in the percentage of diet eaten over time
FE phosphate ¼ urinary concentration of phosphate  plasma creatinine concentration
urinary concentration of creatinine  plasma phosphate concentration  100%
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(P = 0.69). There was no difference between the propor-
tion of cats in each group that died or were euthanized
(2 of 26 test vs. 2 of 28 control, P = 0.34) during the
study (see Fig 2). Assessment of the primary outcome
found no difference in the number or proportion of cats
that developed azotemic CKD in each group (3 of 26
(12%) test vs. 3 of 28 (11%) control, odds ratio 1.09
(95% CI 0.13–8.94), P = 0.92).
The majority of cats in this study ate some wet food
in addition to the study diet provided: 17 of 26 cats
assigned to the test diet and 18 of 28 cats assigned to
the control diet. In all cases, the wet foods offered were
not marketed as a “senior” diet. A variety of brands
were offered, with Whiskas being the most commonly
fed brand. The majority of cats were also offered some
“human” foods, but in all cases, the foods offered were
small amounts, offered occasionally, and no cat received
these foods as a substantial part of their diet. The most
common foods offered were chicken (28 cats) and dairy
(milk, cream, yoghurt, or cheese) (17 cats). Additional
dry foods were offered to a small number of cats: 6 of
26 cats on the test diet and 2 of 28 on the control diet.
However, only 2 cats (one on each diet) received more
than a few kibbles of alternative dry food per day.
A summary of variables examined over time and the
effects of diet are shown in Table 3a and b. Variables that
did not change over time and no effect of diet was seen:
plasma phosphate, logFGF-23 (Fig 3) and potassium
concentrations, SBP, or logUPC. Although UPC concen-
trations were higher in the control diet group at baseline,
there was no difference between the groups at any other
time points (P > 0.57). Total calcium (P = 0.032) and
TT4 concentrations (P = 0.007) increased, while BCS
(P < 0.001), bodyweight (P < 0.001), MCS (P < 0.001),
USG (P = 0.047), and plasma creatinine (P = 0.030)
decreased over time for all cats, independent of diet fed
(Fig 3).
FE phosphate changed significantly over time for
both groups (P = 0.040); in both cases, the change was
nonlinear and the two diets had different effects (see
Fig 4). Posthoc comparisons indicated that FE phos-
phate was significantly higher in cats eating control diet
by 15 months (P = 0.045) and for the remainder of the
study period (all P < 0.05).
Lost to follow-up (n=1)
Owner not contactable
Discontinued intervention (n=12)
Poor compliance at 2 weeks (n=9)
Owner decision (n=1)
Significant medical problem (n=1)
Became aggressive (n=1)
Reached a primary end-point (n=24)
Azotemic CKD (n=3)
Death/euthanasia (n=2)
Euthanasia before visit 2 (n=1)
Reached visit 8 following the protocol 
(n=18)
Lost to follow-up (n=0)
Discontinued intervention (n=11)
Poor compliance at 2 weeks (n=3)
Owner decision at 2 weeks (n=1)
Owner decision at a later visit (n=4)
Significant medical problem (n=3) 
Reached a primary end-point (n=21)
Azotemic CKD (n=3)
Death/euthanasia (n=2)
Reached visit 8 following the protocol 
(n=16)
Analysed (n=26) 
• Excluded from analysis (n=11) (underlined)
No follow-up on intervention (n=10)
Analysed (n=28) 
• Excluded from analysis (n=7) (underlined)
Didn’t receive the intervention (n=3)
No follow-up on intervention (n=4)
Analysis
Follow-Up
Allocated to test diet (n=37)
• Received allocated intervention (n=37)
• Did not receive allocated intervention (n=0)
Allocated to control diet (n=35)
• Received allocated intervention (n=32)
• Did not receive allocated intervention (n=3)
Allocation
Enrolment Assessed for eligibility (n=145)
Excluded (n=73)
• Not meeting inclusion criteria (n=53)
• Declined to participate (n=17)
• Too aggressive to sample (n=3)
Randomized (n=72)
Fig 2. CONSORT 2010 Flow Diagram detailing study population recruitment and handling.
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Ionized calcium concentrations increased over time
for both groups (P = 0.022). Although the magnitude
of the increase was greater for the test diet group, the
size of the effect was small and posthoc comparisons
found no significant difference between the groups at
any individual time points (Fig 4). Ionized hypercal-
cemia (>1.4 mmol/L) was present in two cases at visit 1;
one assigned to each diet and was persistent for the cat
on test diet but normalized for the remainder of the
trial for the cat on control diet. A further 6 cats devel-
oped ionized hypercalcemia during the study period.
One cat assigned to control diet developed ionized
hypercalcemia from visit 4 onwards, with total hyper-
calcemia from visit 6 onwards. Five cats eating test diet
developed ionized hypercalcemia, including 3 cases at
visit 8 (total calcium normal), 1 cat from visit 4
onwards (total calcium always normal), and the cat that
had a pancarpal arthrodesis was transiently hypercal-
cemic for both ionized and total calcium following sur-
gery. Plasma PTH concentrations were below the limit
of detection (LoD) of the assay for all cats at visits
where ionized hypercalcaemia was demonstrated, with
the exception of one cat diagnosed with azotemic CKD
at visit 8 (plasma PTH concentration 14.0 pg/mL).
Plasma FGF-23 concentrations were increased through-
out the study period for the cat that was persistently
hypercalcemic from baseline. Plasma FGF-23 concen-
trations increased to above reference interval in two
cats (one on each diet) that demonstrated persistent ion-
ized hypercalcemia from visit 4 onwards. The propor-
tion of cats that developed ionized hypercalcemia while
eating test diet was higher than for cats eating control
diet, but this failed to reach statistical significance (5 of
26 test vs. 1 of 28 control, P = 0.067).
Of the 240 PTH measurements obtained, 100 (41.6%)
were below the LoD of the assay. PTH was therefore
analyzed as a categorical variable based on a previously
derived reference interval (RI)19 by four categories: (1)
below the assay LoD (<5.2 pg/mL), (2) RI lower half
(5.2–8.8 pg/mL), (3) RI upper half (8.9–17.6 pg/mL),
and (4) above the RI (>17.6 pg/mL), to allow inclusion
of all measurements. There was a significant difference
in plasma PTH concentrations between the two diets
during the study period (P = 0.005); feeding test diet
was associated with no change in PTH over time [odds
ratio (OR) 0.99, 95% confidence interval (CI) 0.96–
1.03, (P = 0.62)], and feeding control diet was associ-
ated with a 7% increase in the odds of progressing to a
higher PTH category per month of the study period
[OR 1.07, 95% CI 1.03–1.12, (P = 0.001)] (Fig 5).
Discussion
In the present study, feeding the moderately protein-
and phosphate-restricted test diet to healthy older cats
was associated with lower FE phosphate and more
stable PTH concentrations but a slightly greater
increase in ionized calcium when compared to the con-
trol diet. There was no difference in the proportion of
cats developing azotemic CKD between groups. Some
cats from both groups were lost before visit 2 because
of poor compliance; however, compliance for all
remaining cats was excellent for the entire 18 month
study.
The groups were well matched at baseline; however,
UPC was higher in the cats assigned to the control diet
group. We consider this likely to be a type I error, as
there was no difference in UPC between groups at any
Table 2. Comparison of variables at visit 1 (baseline) for cats assigned to each diet. The only significant P value
(P < .05) is highlighted in bold.
Test diet (n = 26) Control diet (n = 28)
P value
Mean  SD or Median
[25th, 75th percentiles] n
Mean  SD or Median
[25th, 75th percentiles] n
Age (years) 12.2 [11.2, 13.5] 26 12.1 [11.1, 13.9] 28 0.92
Creatinine (mg/dl) 1.5  0.2 26 1.6  0.2 28 0.73
Urea (mg/dl) 28.3  5.6 26 27.2  4.5 28 0.41
Ionized calcium (mg/dl) 1.27  0.08 20 1.3  0.06 24 0.24
Total calcium (mg/dl) 9.76  0.60 26 9.88  0.60 28 0.48
Phosphate (mg/dl) 3.88  1.21 26 3.50  0.50 28 0.14
PTH (pg/ml) 7.7 [2.6, 10.1] 25 6 [2.6, 11.4] 28 0.36
FGF-23 (pg/ml) 153.4 [105.1, 208.6] 25 124.3 [99.2, 209.9] 28 0.31
SBP (mmHg) 132  25 26 133  22 28 0.88
Weight (Kg) 4.96  1.29 26 4.54  0.93 28 0.17
BCS (1 to 9) 6  1.4 26 6  1.41 28 0.34
UPC 0.13 [0.11, 0.17] 13 0.20 [0.15, 0.24] 15 0.045
USG 1.048  0.01 13 1.042  0.014 15 0.23
TT4 (nmol/l) 22.8  7.9 26 22.6  8.9 28 0.91
Sex 18 MN, 8 FN 12 MN, 16 FN
Breeds 23 DSH, 3 DLH 21 DSH, 5 DLH,
1 BSH, 1 Chinchilla X
n, number of cats in group; SBP, systolic blood pressure; BCS, body condition score; UPC, urine protein-to-creatinine ratio; USG, urine
specific gravity; TT4, plasma total thyroxine concentration; MN, male neutered; FN, female neutered; DSH, domestic shorthair; DLH,
domestic longhair; BSH, British Shorthair.
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Table 3. (a and b): Linear mixed model analysis of changes in variables during the study period showing (a) sum-
mary of P values for terms included in the models and (b) summary of intercepts and slopes (n = 54).
Variable Diet Time Diet*Time Time2
(a)
Weight (Kg) 0.20 0.98 0.067 0.011
Ionised calcium (mmol/L) 0.48 0.59 0.018 0.022
FE phosphate (%) 0.61 0.021 0.045 0.040
BCS (1 to 9) 0.80 <0.001 NS NS
MCS 0.52 <0.001 NS NS
Total T4 (nmol/L) 0.75 0.007 NS NS
Creatinine (mg/dL) 0.66 0.030 NS NS
Total calcium (mg/dL) 0.58 0.032 NS NS
USG 0.84 0.047 NS NS
logUPC 0.39 0.090 NS NS
SBP (mmHg) 0.39 0.29 NS NS
logFGF23 (pg/ml) 0.11 0.32 NS NS
Potassium (mEq/L) 0.95 0.76 NS NS
Urea (mg/dL) 0.92 0.84 NS NS
% study diet eaten 0.82 0.84 NS NS
Phosphate (mg/dL) 0.35 0.89 NS NS
Variable
Test Diet Control Diet
Intercept Slope of Time Slope of Time2 Intercept Slope of Time Slope of Time2
(b)




1.28  0.013 0.0002  0.002 0.0002  8.02E-05 1.30  0.013 (0.002)  0.002 0.0002  8.02E05
FE
phosphate (%)
40.5  2.8 (1.83)  0.64 0.066  0.032 38.6  2.7 (1.15)  0.65 0.066  0.032
BCS (1 to 9) 6.05  0.22 (0.021)  0.006 NA 5.97  0.21 (0.021)  0.006 NA
MCS (1 to 4) 3.69  0.075 (0.016)  0.004 NA 3.63  0.073 (0.016)  0.004 NA
Total T4
(nmol/L)
22.9  1.8 0.30  0.11 NA 22.1  1.8 0.30  0.11 NA
Creatinine
(mg/dL)




9.89  0.11 0.009  0.004 NA 9.81  0.11 0.009  0.004 NA
USG 1.046  0.003 (0.0002)  0.0001 NA 13045  0.003 (0.0002)  0.0001 NA
logUPC (0.82)  0.04 0.002  0.001 NA (0.78)  0.03 0.002  0.001 NA
SBP (mmHg) 130.5  2.8 (0.12)  0.11 NA 133.8  2.8 (0.12)  0.11 NA
logFGF23
(pg/mL)
2.20  0.05 (0.001)  0.001 NA 2.09  0.05 (0.001)  0.001 NA
Potassium
(mEq/L)
3.99  0.05 0.0007  0.0023 NA 3.99  0.049 0.0007  0.0023 NA
Urea
(mg/dL)
27.5  1.02 (0.007)  0.04 NA 27.4  0.99 (0.007)  0.04 NA
% study diet
eaten
84.9  2.6 (0.014)  0.069 NA 84.1  2.5 (0.014)  0.069 NA
Phosphate
(mg/dL)
3.73  0.09 0.0007  0.005 NA 3.61  0.09 0.0007  0.005 NA
Outcome variables showing significant change over time and between groups (P < .05) are highlighted in bold. The unit used for time
was month (28 days). Diet represents cats assigned to test or control diet.
The term diet*time2 was not significant in any models and is therefore not included in the table. A significant effect of time2 indicates a
significant nonlinear change in both groups during the study period. If time2 was not significant (NS), this term was removed from the
model.
A significant interaction in diet*time indicates the rate of change of the outcome variable differed between diets and therefore indicates a
difference between feeding test or control diet. If diet*time was not significant, it suggests that any change in the outcome variable occurred
in all cats independent of which diet they were assigned to and the term was therefore removed from the model.
For models where diet*time was NS, a significant change in time indicates the outcome variable significantly increased or decreased dur-
ing the study period and that the change seen was linear.
For linear changes over time, the slope of time2 is not applicable (NA).
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other time point and no effect of diet on UPC over
time.
FE phosphate was significantly lower in cats eating
the test diet compared to those eating the control diet.
This was expected, because maintaining stable total
body phosphate should require a decrease in phosphate
excretion if phosphate intake is reduced (and GFR does
not change). Exact phosphate intake during the study
could not be determined in these cats because reported
dietary intake by owners could not be verified. This is a
potential limitation; however, the results more accu-
rately reflect the situation in the clinic than results from
Fig 3. Scatter plots of plasma total calcium, creatinine and TT4 concentrations, USG, bodyweight and BCS for cats eating the test or
control diets during the study period. All changes over time were linear (except for bodyweight) and were independent of which diet the
cats were eating. There was a significant increase in plasma total calcium (P = 0.032) and TT4 (P = 0.007) concentrations and a significant
decrease in plasma creatinine concentrations (P = 0.030), body condition score (P < 0.001), and urine specific gravity (P = 0.047) during
the study period. Bodyweight decreased significantly over time (P = 0.011), and this change was independent of which diet the cats were
eating. The change over time was nonlinear.
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studies that use laboratory cats. Interestingly, FE phos-
phate was not significantly different between the groups
until the 15-month time point and at the beginning of
the study period it decreased in all cats. This suggests
that dietary phosphate load was higher or more
bioavailable in the varied baseline diets than both the
test and control diets. This may be because of the feed-
ing of more high-protein “treats” such as meat, fish,
and dairy products before the study. On enrollment,
owners were requested not to feed fish and to minimize
treats, particularly in overweight cats. Ideally all cats
would have had a wash-in period before the start of the
study in which they all received the same diet. This was
not performed as it would have required additional
sampling in these healthy cats and might have reduced
compliance with the study protocol in these client-
owned animals. However, given the long timecourse of
this study, it need not be considered a substantial study
limitation.
Plasma phosphate and FGF-23 concentrations
remained stable for all cats during the study. It is possi-
ble that no difference was seen between the groups
because there was not enough difference in phosphate
content between the two diets. Alternatively, it could be
expected that plasma phosphate concentrations would
not change in these healthy cats, because plasma phos-
phate concentration does not change when feeding a
more markedly phosphate-restricted diet (<1.1 g/Mcal)
to CKD cats that are normophosphatemic for their
IRIS stage.19 However, plasma FGF-23 concentrations
do decrease significantly in all CKD cats fed a diet with
<1.1 g/Mcal phosphate.19 Additionally, short-term diet-
ary phosphate restriction (maximum study duration
4 weeks) in healthy people decreases FGF-23 concentra-
tions.24–27 Therefore, plasma FGF-23 concentrations
were expected to decrease in cats fed the test diet in the
present study. As plasma phosphate concentrations
were stable for all cats, the lack of change in FGF-23
might be an appropriate physiologic response, but FE
of phosphate decreased on both diets. Additionally,
Fig 4. Scatter plots of whole blood ionized calcium concentration
and FE phosphate for cats eating the test and control diets during
the study period. All changes over time were nonlinear. Ionized
calcium increased significantly over time (P = 0.022), and there
was a difference between cats eating test diet and cats eating con-
trol diet over time (P = 0.018). However, post hoc comparisons
revealed no significant difference between the cats on the different
diets at any individual time points during the study period. FE
phosphate initially decreased and subsequently increased during
the study period (P = 0.040), and there was a difference between
cats eating test diet and cats eating control diet over time
(P = 0.045). Post hoc comparisons found that FE phosphate was
significantly lower in cats eating test diet at the 15 month time
point (P = 0.045) and for the remainder of the study period.
Fig 5. Bar charts of the percentage of cats in each PTH category
at each sampling visit for cats eating the test and control diets dur-
ing the study period. There was a significant difference between
cats assigned to the test vs. control diet over the study period
(P = 0.005). Cats fed the test diet demonstrated no significant
change in PTH category during the study period (P = 0.62). Cats
fed the control diet demonstrated a significant increase of 7% in
the odds of moving up a PTH category for every month of the
study period (P = 0.001).
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there was no decrease in PTH concentrations in either
group. This raises the question of what was responsible
for the change in phosphate excretion if not FGF-23
(or PTH), unless the timing of sampling, or the assay
used for FGF-23 measurement prevented subtle changes
in this hormone being detected.
Circulating FGF-23 concentrations do not change
acutely postprandially in healthy humans28 or those
with early CKD29 and do not demonstrate a circadian
rhythm in healthy humans or hemodialysis patients.30,31
These observations have not been examined in the cat,
but to minimize the effect of eating and of circadian
variation on all parameters, owners were telephoned the
day before every appointment to remind them to starve
their cats for at least 8 hours and appointments were
conducted in the mornings. Studies of murine mod-
els,32,33 of healthy humans25,26 and CKD patients,34,35
have revealed variable responses of urinary phosphate
excretion, serum phosphate, and serum FGF-23 concen-
trations with changes in dietary phosphate load. One
study of 16 normophosphatemic stage 3 or 4 CKD
patients randomized in a 2 9 2 factorial design to diets
with different phosphate loads (P)  a phosphate binder
(PB) (750 mg P + PB, 1500 mg P + placebo, 750 mg P
+ placebo, 1500 mg P + PB daily) for 2 weeks found no
significant changes in serum phosphate or FGF-23 con-
centrations in any group, but significant reductions in
24-hour phosphate excretion were seen in all groups
except the group receiving the highest dietary phosphate
load (1500 mg + placebo).36 It seems, therefore, that
dietary phosphate load can alter urinary phosphate
excretion via a mechanism independent of FGF-23.
Infusion of phosphate into the duodenum and intra-
venous infusion of duodenal extracts into rats induce a
rapid increase in FE phosphate.37 This is independent
of FGF-23, PTH, and the phosphatonin sFRP-4 and is
unchanged by denervation of the kidney. Therefore, it
has been proposed that the duodenal mucosa secretes a
phosphatonin-like substance which induces a rapid
increase in the fractional excretion of phosphorus.37
However, to date, the substance(s) involved in this gut-
renal axis remain unknown. Furthermore, although the
presence of a phosphate-sensing mechanism in various
organs has been postulated,38 this also remains to be
elucidated.
Cats fed the test diet had no change in plasma PTH
concentrations throughout the trial, whereas PTH con-
centration increased in cats fed the control diet. The
majority of these increases occurred within the reference
interval. It is difficult to assess the definitive cause of
this difference between groups. The control diet had a
slightly lower calcium:phosphate (Ca:P) ratio (1.10)
than the test diet (1.21), which may have been a stimu-
lus of PTH secretion; however, ionized calcium
increased over time in both groups. Alternatively, the
change in PTH for cats eating the control diet may
reflect an age-related increase. Age has previously been
shown to be a predictor of increasing PTH in both
humans39,40 and cats.15 PTH is increased at baseline for
cats that develop azotemia over 12 months, compared
to cats remaining nonazotemic.15 It is not possible to
assess the effect that these differences in PTH concentra-
tion had, if any, on the progression of CKD in the pre-
sent study, as the proportion of cats that developed
azotemia was low in both diet groups. Additionally,
measurement of PTH in this study was hampered by
poor sensitivity of the assay, resulting in 41.6% of sam-
ples being below the LoD. Unfortunately, currently,
there are no validated PTH assays for use with feline
samples that do not have poor sensitivity.41 The assay
used in this study measures intact PTH and has been
validated previously.42,43 An assay measuring biologi-
cally active “whole” PTH molecule has also been vali-
dated, but has not been found to offer advantage over
the intact PTH assay.42
Total calcium concentrations increased in all cats
during the study (independent of diet). Both diets could
have had greater calcium bioavailability than the mix-
ture of diets fed at baseline or could have resulted in a
similar increase in calcium absorption, bone resorption,
or reduced calcium excretion. Alternatively, total cal-
cium may increase with age. In contrast, apparently
healthy cats >10 years of age in Belgium have signifi-
cantly lower total calcium concentrations than cats 6–
10 years old.44 Another study found a negative effect of
age on plasma total calcium concentrations in 525
healthy purebred cats, but deemed it to be clinically
irrelevant when establishing a reference range.45 Ionized
calcium concentrations also increased during the study
period, but there was a significant difference in this
change between the groups. The increase in calcium
does not appear to be PTH-mediated, as the test diet
was associated with stable PTH but a greater increase
in ionized calcium. Additionally, it does not appear to
be vitamin D-mediated as both diets had the same vita-
min D concentration, and both diets had were mildy
acidifying (urine pH 6–6.5) and therefore will not have
induced difference in urinary calcium excretion. Devel-
opment of ionized hypercalcemia occurred in five cats
eating test diet and only one cat eating control diet;
however, this difference was not significant. It is possi-
ble that these cats developed idiopathic hypercalcemia,
independent of dietary calcium/phosphate load. How-
ever, feeding a substantially phosphate-restricted renal
diet has previously been associated with development of
ionized hypercalcemia in azotemic cats.22 It is plausible
that moderate dietary phosphate restriction could
induce ionized hypercalcemia via the same (undeter-
mined) mechanism in healthy cats and although the
consequence of this is unclear, it should be considered
when advising on diets for healthy older cats, as it
might increase the risk of developing calcium-containing
uroliths.
TT4 concentrations gradually increased for all cats
during the study, but only one cat was diagnosed with
hyperthyroidism. A previous prospective study reported
an annual incidence of hyperthyroidism diagnosis of
7.4% in cats with a median age of 12 years;46 however,
cats in the present study were excluded if on screening,
their TT4 > 40 nmol/L. The consequence of the gradual
increase in TT4 seen during the present study is
unknown, but were this increase to continue, more of
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these cats would go on to become hyperthyroid over
time, which would not be unexpected because increasing
age is an independent risk factor for development of
feline hyperthyroidism.47
Bodyweight and BCS decreased in both groups dur-
ing the study period. At enrollment, 61% (33 of 54) of
the cats had a BCS of 6 of 9 or greater and owners
were instructed how much to feed their cats and
encouraged to weigh the food. Thus, part of the
observed reduction in bodyweight may indicate success-
ful reduction in body fat. However, MCS also
decreased over time in both groups. Although data on
sarcopenia in cats are currently lacking, it is well recog-
nized in humans and to a lesser extent in dogs that lean
body mass declines during aging,48 which could be one
explanation for the decrease in MCS seen during this
study period. Alternatively, lean body mass of cats can
be affected by protein intake;49 however, additional
studies are required to investigate this relationship in
older cats.
Plasma creatinine concentration decreased during the
study in cats on both diets. The mean decrease in crea-
tinine was small (0.12 mg/dL) and is likely a result of
the reduction in lean body mass or is possibly sec-
ondary to an increase in GFR mediated by the increase
TT4. USG significantly decreased gradually over time
for cats on both diets, but in isolation is an unreliable
indicator of renal function as this change could have
been secondary to other changes, for example, reduced
protein intake. A cross-sectional study of apparently
healthy older cats found no significant difference
between serum creatinine concentrations or USG in cats
>10 years and cats 6–10 years of age; however, in agree-
ment with the results of the present study, mean crea-
tinine and USG were slightly lower in the older cats
and the paired design of the present study gives it
greater power to detect differences.44
The test diet was higher in x-3 PUFA than the con-
trol diet, which at high doses have renoprotective effects
in experimental canine models of kidney disease,50
although it is not possible from this study to assess
whether the increased concentration of x-3 PUFA had
effects on the cats’ renal function. It is also possible that
this difference could have had an impact on calcium-
phosphate homeostasis as there is emerging evidence
that x-3 PUFA supplementation might reduce bone
turnover in postmenopausal women.51,52 Markers of
bone turnover were not examined in this study; how-
ever, ionized calcium concentrations increased more
greatly in the test diet group, which could be a result of
decreased calcium deposition in bone. Further studies
into the effects of x-3 PUFA in cats are warranted.
This trial recruited client-owned cats to improve its
generalizability to veterinary clinical practice. A limita-
tion of this study is that the randomization of cats to
either test or control diet was skewed for cats in multi-
cat households; however, this was considered necessary
to ensure compliance with the assigned diet. The study
was not subjected to an intention-to-treat analysis
because of the duration of the trial. Failure of cats to
eat the assigned diet would have had a substantial
impact on the comparison between test and control
diets and bias the estimate of the effects of feeding the
test diet. Therefore, to address the aims of this study, it
was considered judicious to analyze data only from cats
that had at least one follow-up visit on the intervention.
Data on compliance are presented to show what level
of acceptance of dietary change can be achieved in cats
of this age bearing in mind the incentive to owners of
receiving diet free of charge. The majority of cats ate
other foods during the study. Although fish was not
consumed (because of the high x3 PUFA content), and
quantities of fresh meat and dairy were low, 17–18 cats
in each group regularly ate a wet maintenance diet cat
food. This is a limitation of the study as it is difficult to
quantify the additional phosphate consumed by these
cats, which may have impacted on the ability to see an
effect of the test diets on calcium-phosphate homeosta-
sis. Future studies aiming to examine the effect of feline
diets in client-owned cats should be aware that pet own-
ers may not be willing to feed one diet type exclusively.
Various medications were administered to cats during
the study period in both groups, as needed based on
clinical judgement. The most frequently prescribed med-
ications were NSAIDs for osteoarthritis. It is difficult to
assess the impact these medications may have had, if
any, on the study outcomes. However, the proportion
of cats requiring long-term NSAIDs was not signifi-
cantly different between groups and the need for pain
relief to manage osteoarthritis commonly occurs in
older cats. Therefore, the use of these medications in
this study cohort reflects the wider management of
older cats in veterinary clinical practice.
Only 11% (6 of 54) of cats were diagnosed with azo-
temic CKD during the present study. A previous
prospective study, where no attempt was made to mod-
ify the cats’ diets during the study period, found 30.5%
of cats developed azotemic CKD within 12 months.3
The disparity between these studies may be attributable
to having a slightly younger population of cats in the
present study, 12.2 [11.2, 13.8] years, compared to 13.0
[11.0, 15.0] years in the previous study. Given the very
low rate of azotemia development in this study popula-
tion, thousands of cats would have been needed to
detect a significant difference in development of azote-
mic CKD between groups with these two diets. Recruit-
ing very large numbers of cases for clinical veterinary
studies is difficult. Further studies should therefore con-
sider using diets with greater difference in protein and
phosphate content, following cats for longer periods, or
assessing renal function with GFR measurements to
assess whether protein and phosphate restriction can
have beneficial effects in preazotemic CKD cats.
In conclusion, feeding the test diet to healthy older
cats was associated with a decrease in FE phosphate,
and a greater increase in ionized calcium concentration
when compared to cats fed the control diet. Cats eating
the control diet had a significant increase in PTH con-
centration during the study period, which was not
observed for cats fed the test diet. However, it is not
possible to conclude whether feeding the test diet bene-
fited renal function; further investigations in
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nonazotemic cats should consider using an older popu-
lation, or following cats for longer than 18 months, to
evaluate more thoroughly the effect of protein and
phosphate restriction on renal function.
Footnotes
a Istin, Pfizer, Sandwich, Kent, UK




d ISTAT, Woodley Equipment, UK
e Idexx laboratories, Wetherby, UK
f FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan
g Total intact PTH immunoradiometric assay – coated bead ver-
sion, 3KG600, Scantibodies, Santee, CA
h IBM SPSS Statistics 21, IBM Corporation, Armonk, NY
i Prescription diet w/d Feline, Hills Pet Nutrition Inc., Topeka,
KS
j Felimazole, Dechra Veterinary Products Limited, Northwich,
UK. A dose of 2.5 mg q12h was administered for 28 days, fol-
lowed by a dose adjustment to 2.5 mg alternating with 5 mg
q12h, which was maintained for the remainder of the study
period
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